CA2840637A1 - Produit pharmaceutique et procede d'analyse de l'exposition lumineuse d'un produit pharmaceutique - Google Patents

Produit pharmaceutique et procede d'analyse de l'exposition lumineuse d'un produit pharmaceutique Download PDF

Info

Publication number
CA2840637A1
CA2840637A1 CA2840637A CA2840637A CA2840637A1 CA 2840637 A1 CA2840637 A1 CA 2840637A1 CA 2840637 A CA2840637 A CA 2840637A CA 2840637 A CA2840637 A CA 2840637A CA 2840637 A1 CA2840637 A1 CA 2840637A1
Authority
CA
Canada
Prior art keywords
photosensitive
active ingredient
property change
change
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2840637A
Other languages
English (en)
Inventor
Jeremy GUO
Deborah Shnek
Paula SPENCER
Li Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA2840637A1 publication Critical patent/CA2840637A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D79/00—Kinds or details of packages, not otherwise provided for
    • B65D79/02—Arrangements or devices for indicating incorrect storage or transport
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01D—MEASURING NOT SPECIALLY ADAPTED FOR A SPECIFIC VARIABLE; ARRANGEMENTS FOR MEASURING TWO OR MORE VARIABLES NOT COVERED IN A SINGLE OTHER SUBCLASS; TARIFF METERING APPARATUS; MEASURING OR TESTING NOT OTHERWISE PROVIDED FOR
    • G01D7/00—Indicating measured values
    • G01D7/005—Indication of measured value by colour change

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Details Of Rigid Or Semi-Rigid Containers (AREA)
  • Packages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2840637A 2011-09-02 2012-08-31 Produit pharmaceutique et procede d'analyse de l'exposition lumineuse d'un produit pharmaceutique Abandoned CA2840637A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530824P 2011-09-02 2011-09-02
US61/530,824 2011-09-02
PCT/US2012/053450 WO2013033600A1 (fr) 2011-09-02 2012-08-31 Produit pharmaceutique et procédé d'analyse de l'exposition lumineuse d'un produit pharmaceutique

Publications (1)

Publication Number Publication Date
CA2840637A1 true CA2840637A1 (fr) 2013-03-07

Family

ID=46982918

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2840637A Abandoned CA2840637A1 (fr) 2011-09-02 2012-08-31 Produit pharmaceutique et procede d'analyse de l'exposition lumineuse d'un produit pharmaceutique

Country Status (13)

Country Link
US (1) US20140315187A1 (fr)
EP (1) EP2750989A1 (fr)
JP (1) JP2014529473A (fr)
KR (1) KR20140058669A (fr)
CN (1) CN103917458A (fr)
AU (1) AU2012301656A1 (fr)
BR (1) BR112014004591A2 (fr)
CA (1) CA2840637A1 (fr)
CL (1) CL2014000104A1 (fr)
EA (1) EA201490555A1 (fr)
MX (1) MX2014002533A (fr)
WO (1) WO2013033600A1 (fr)
ZA (1) ZA201309704B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113454438A (zh) * 2019-02-22 2021-09-28 科慕埃弗西有限公司 用于确定材料的感光特性的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016202785A1 (fr) 2015-06-17 2016-12-22 Novozymes A/S Contenant
IL250601B (en) * 2017-02-14 2018-05-31 Marpaz Tech Ltd Container for light sensitive material

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0117390B1 (fr) * 1983-02-25 1990-09-05 Lifelines Technology, Inc. Procédé de surveillance de l'exposé incrémental à l'environnement des produits, subissant des changements de qualité progressifs suite aux stimulations extérieures
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP0417563B1 (fr) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag Protéines qui lient le TNF
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
JPH06174600A (ja) * 1992-09-16 1994-06-24 Caterpillar Inc 状態変化を表示する方法および装置
DE69332981T2 (de) 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
NZ311982A (en) 1995-06-29 1999-08-30 Immunex Corp Tnf related apoptosis inducing ligand (trail), a method for producing them and associated antibodies
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2001036637A1 (fr) 1999-11-17 2001-05-25 Immunex Corporation Activateur du recepteur de nf-kappa b
CA2407956A1 (fr) 2000-05-03 2001-11-08 Amgen Inc. Peptides modifies utilises comme agents therapeutiques

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113454438A (zh) * 2019-02-22 2021-09-28 科慕埃弗西有限公司 用于确定材料的感光特性的方法

Also Published As

Publication number Publication date
JP2014529473A (ja) 2014-11-13
US20140315187A1 (en) 2014-10-23
BR112014004591A2 (pt) 2017-03-28
WO2013033600A1 (fr) 2013-03-07
EP2750989A1 (fr) 2014-07-09
AU2012301656A1 (en) 2014-01-16
EA201490555A1 (ru) 2014-07-30
MX2014002533A (es) 2014-08-26
CL2014000104A1 (es) 2014-07-25
CN103917458A (zh) 2014-07-09
KR20140058669A (ko) 2014-05-14
ZA201309704B (en) 2014-08-27

Similar Documents

Publication Publication Date Title
Le Basle et al. Physicochemical stability of monoclonal antibodies: a review
Lubiniecki et al. Comparability assessments of process and product changes made during development of two different monoclonal antibodies
Narhi et al. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: part 1, considerations and strategy
Alsenaidy et al. Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles
ES2349885T3 (es) Análisis de la citotoxicidad celular que depende de anticuerpos.
Kiyoshi et al. Collaborative study for analysis of subvisible particles using flow imaging and light obscuration: experiences in Japanese biopharmaceutical consortium
Jones et al. Complementary MS methods assist conformational characterization of antibodies with altered S–S bonding networks
CN102695956B (zh) 用于检测对治疗性抗IgE抗体特异性的抗体的测定法及其在过敏反应中的用途
US20140315187A1 (en) Pharmaceutical Product and Method of Analysing Light Exposure of a Pharmaceutical Product
Shi et al. Recognition of human IgG1 by Fcγ receptors: structural insights from hydrogen–deuterium exchange and fast photochemical oxidation of proteins coupled with mass spectrometry
CN1668721B (zh) 含有糖蛋白ⅵ结构域的免疫粘附素
ES2905615T3 (es) Sistemas y métodos para evaluar moduladores de puntos de control inmunitario
US20170210821A1 (en) Antibodies that Recognize Red Blood Cell Antigens
Prior et al. International standards for monoclonal antibodies to support pre-and post-marketing product consistency: Evaluation of a candidate international standard for the bioactivities of rituximab
Kagdi et al. Determination of holdup volume and transient contact compatibility of closed system transfer devices for a reconstituted lyophilized drug product
JP2023068027A (ja) 免疫チェックポイント阻害剤ｐｄ－１及びｐｄ－ｌ１に対する抗体治療をモニタリングするためのイムノアッセイ及び操作されたタンパク質
Schreiber et al. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
US20210318333A1 (en) Methods of glycoprotein analysis
Ambrogelly The different colors of mAbs in solution
Kim et al. Evaluation of the physicochemical and biological stability of reconstituted and diluted SB2 (infliximab)
Gurel et al. Structural and functional analysis of CEX fractions collected from a novel avastin® biosimilar candidate and its innovator: a comparative study
IL294765B2 (en) Deglycosylation methods for electrophoresis of glycosylated proteins
CA2999866C (fr) Composition et methodes pour evaluer la sensibilite et la specificite de reactifs de detection d'anticorps
Demirhan Stability Evaluation of the Biosimilar Monoclonal Antibody Using Analytical Techniques
Doevendans et al. Protein quality testing in the era of personalized medicine

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20160831